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ABSTRACT
Simpson, Lance L.: Blood pressure and heart rate responses
evoked by p-hydroxyamphetamine and byp-hydroxynorephed-
rine. II. A quantitative assessment of the role of amphetamine
metabolltes in acute responses evoked by d-amphetamine. J.
Pharmacol. Exp. Ther. 21 3: 504-508, 1980.
At postganglionic sympathetic sites, p-hydroxyamphetamine is
neither a receptor agonist nor a receptor antagonist; in addi-
tion, the drug does not act presynapticaliy to antagonize or
synergize d-amphetamine. p-Hydroxyamphetamine is an mdi-
rectly acting sympathomimetic amine with a potency approxi-
mately twice that of d-amphetamine. In the rat, a large fraction
(‘-.‘0.5) of d-amphetamine is biotransformed to p-hydroxyam-
phetamine. However, the rate of biotransformation to p-hy-
droxyamphetamine (---0.0099 - min1) is slow compared to the
rate of elimination of p-hydroxyamphetamine (0.049 . min).
As a result, plasma levels of d-amphetamine exceed those of
p-hydroxyamphetamine. The kinetic data suggest that: 1 ) p-
hydroxyamphetamine plays little role in immediate responses
to single injections of d-amphetamine; 2) p-hydroxyampheta-
mine is not involved in tachyphylactic responses to repeated
injections of d-amphetamine; and 3) p-hydroxynorephedrine
plays no role in immediate or tachyphylactic responses to d-
amphetamine.
Acute responses to d-axnphetamine involve at least two phe-
nomena: 1) the immediate response that results from a single
injection of the drug and 2) the tachyphylactic response that
results from repeated injections of the drug. The purpose of the
present report is to determine whether the hydroxylated me-
tabolites of d-amphetamine,p-hydroxyamphetamine and p-hy-
droxynorephedrine are involved in either of these phenomena.
A determination of whether a drug metabolite is involved in
responses evoked by a parent compound requires at least the
following information: 1) the mechanism of action of the me-
tabolite and the relationship this bears to the mechanism of
action of the parent compound; 2) the potencies of the parent
compound and the metabolite; 3) the fractional conversion of
the parent compound to the metabolite; and 4) the rate con-
stants for formation and elimination of the metabolite. This
information has been acquired with particular emphasis on the
primary metabolite p-hydroxyamphetamine. The data have
been used to quantify the role of amphetamine metabolites in
acute responses to d-amphetamine.
Materials and Methods
Animals. Male Sprague-Dawley rats (Camm Research Institute,
Wayne, NJ) weighing between 200 and 245 g were used in these studies.
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The rats are a pathogen-free strain that is Caesarean derived and
barrier reared. These animals are different from those used in previous
studies (Simpson, 1978a,b). The pathogen-free strain metabolizes d-
amphetamine more quickly (see fig. 3) and thus it is well suited for
experiments aimed at evaluating the action of metabolites.
Recording ofblood pressure and heart rate. Blood pressure and
heart rate responses were recorded as previously described (Simpson,
1979). Cardiovascular responses were recorded in animals that had
been pretreated with a muscarinic cholinergic blocking agent (atropine
methyl bromide, 25 mg/kg i.p.) and with a gangliomc blocking agent
(chiorisondamine, 1 mg/kg i.p.). These pretreatments ensured that
neither tonic nor reflex neural activity would obscure the actions of d-
amphetamine and its metabolites in the periphery. During blood pros-
sure and heart rate experiments, animals were anesthetized. During
short experiments (evoked responses <30 mm duration), the anesthetic
agent was psntobarbital sodium (50 mg/kg i.p.). During infusion exper-
iments (evoked responses -3 hr duration), the anesthetic agent was
urethane (1.5 g/kg i.p.). The latter agent was used during lengthy
experiments to eliminate the possibility ofbarbiturate-induced changes
in hepatic hydroxylation of d-amphetamine. When animals were anes-
thetized their body temperatures were maintained at 35-36#{176}C (Ther-
mistemp temperature controller, Yellow Springs Instrument Co., Ye!-
low Springs, OH).
Adminisfration of d-amphetamine and p-hydroxyampheta-
mine. Drugs were administered intravenously either as a bo!us or as
an infusion. In both cases, the drugs were dissolved in saline (0.154 M
NaC1). For bo!us injections, the volume of saline that was injected
varied with body weight (1 mI/kg). For infusions, all animals received
a volume of 8 d/min. d-Amphetamine and its metabolites were given


































mean arterial blood pressure and heart rate were always stable: the
respective values (mean ± S.D.) were: 71 ± 4 mm Hg and 263 ± 6
beata/min.
Assay for d-amphetamine and for p-hydroxyamphetamine.
Assays were performed to determine the plasma half-life of d-amphet-
amine and its primary metabolite. The assay procedure forp-hydroxy-
amphetamine has been described (Simpson, 1979). d-Amphetamine
was assayed by using a procedure similar to that of Belvedere et al.
(1973). In brief, the procedure is as follows. Plasma was deproteinized
by adding to it an equal volume of acetone-formats (85:15, v/v). The
mixture was centrifuged (-‘5OO0 g), after which the supernatant was
alkalinized (pH > 10, 5 N NaOH) and saturated with NaCL d-Amphet-
amine was then partioned into toluene by gentle shaking (--10 mm).
The organic phase was collected and mixed with a derivatizing agent
(1% trichloroacetyl chloride, 40#{176}C,30 mm). The mixture was subse-
quently blown to dryness under a stream of nitrogen. Derivatized d-
amphetamine was resuspended in toluene for injection into a gas
chromatograph. A standard curve was generated by adding known
amounts of d-amphetamine to plasma. Tranylcypromine served as an
internal standard.
Standards and unknowns were injected into a Hewlett Packard gas
chromatograph (HP 5007A) equipped with a linear electron capture
detector (model 18713A). Conditions for assay were as follows: oven,
200#{176}C;port, 250#{176}C;and detector, 300#{176}C.On a support of OV-17, 1% d-
amphetamine emerged at -5.8 miii and tranylcypromine emerged at
10.6 mlii. Unknowns were quantified by the method of peak height
ratio (d-amphetamine/tranylcypromine).
Chemical sympathectomy. Animals were sympathectomized as
previously described (Simpson, 1979). 6-Hydroxydopamine was admin-
istered intravenously in a saline vehicle that contained ascorbate (0.01
M). A dose of 50 mg/kg was administered on day 1 and an additional
injection of 100 mg/kg was given on day 3. On day 5, animals were used
for in vivo dose-response studies.
Drugs The drugs used were: d-amphetamine sulphate and p-hy-
drcxyamphetamine hydrobromide (gifts from Smith Kline and French
Laboratories, Philadelphia, PA); iprindole hydrochloride (gift from
Wyeth Laboratories, Inc., Philadelphia, PA); chlorisondamine chloride
(gift from Ciba Pharmaceutical Co., Summit, NJ); atropine methyl
bromide (Mann Research Laboratories, Inc., New York, NY); and 6-
hydroxydopamine hydrobromide, l-norepinephrine bitartrate and dl-
propranolol hydrochloride (Sigma Chemical Co., St. LoWs, MO). The
vehicle for all injections was saline; the volume of fluid administered
varied with body weight (1 nil/kg). All drug dosages are expressed as
the free base.
Data. In the figures and in the text data are presented as the average
response ± S.D. Whenever appropriate, the method of least squares
was used to fit curves to data point8 Statements about Statistical
significance refer to the use of the Student’s t test.
Results
An evaluation ofp-hydroxyamphetamine as an antag-
01,1st or as a synergist of d-amphetamine. Various doses of
norepinephrine were administered to animals that had been
chemically sympathectomized and induced changes in heart
rate were monitored (fig. 1). A similar procedure was used on
animals to whomp-hydroxyamphetamine was being constantly
infused (0.54 tg/min, 60 mm). The infusion procedure is one
that evokes a half-maximal heart rate response in nonsympa-
thectomized animals (Simpson, 1979). The infusion of p-hy-
droxyamphetamine to sympathectomized animals did not itself
induce changes in heart rate nor did it alter norepinephrine-
induced changes in heart rate. dl-Propranolol attenuated re-
sponses to norepinephrine.
A separate group ofanimals (not sympathectomized) received
multiple injections of d-amphetamine and p-hydroxyampheta-
mine, as indicated in figure 2. An examination of induced
changes in heart rate reveals that: 1) p-hydroxyamphetamine
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Fig. 1 . Heart rate responses to noreplnephrine. Various doses of
norepinephrine were administered intravenously to control animals
(0), to animals In whom p-hydroxyamphetamine (p-OHA) was being
infused (0.54 ig/min, 60 mm. #{149})and to animals that had been
pretreated with propranolol (5 mg/kg, . All animals had been chem-
ically sympathectomized; control animals and propranolol pretreated
animals were infused with saline. Each data point represents the mean
± S.D. of responses from five or more animals. The infusion of p-
hydroxyamphetamine did not evoke heart rate responses and It did not




Fig. 2. Heart rate responses to d-amphetamine (#{149})p-hydroxyamphet-
amine (0) and to a combination of the two (). The drugs were tested
individually at two doses, 3 x 1 0 and 1 x I 0_2 mg/kg. The drugs
were tested in combination (50% of each) at cumulative doses of 3 x
1  and 1 x 1 02 mg/kg. Each animal received one injection of each
drug dose or drug combination. The data indicate that the metabolite
is slightly more potent than the parent compound, and that when
administered together, the parent compound and the metaboilte act In
an additive manner.
was slightly more potent than d-amphetamine and 2) when
administered together, d-amphetamine and p-hydroxyamphet-
amine acted in an additive manner.
Plasma half-life of d-amphetamlne and rate of forma-
tion ofp-hydroxyamphetamlne. Groups of animals (group
n = 5) were injected with one of two doses of d-amphetamine
(1 mg/kg, 10 mg/kg i.p.), after which plasma half-life of the
drug was determined (fig. 3). Half-life was independent of
amount of administered drug (1 mg/kg, T112 34 mm; 10 mgI
kg, T112 . 36 mm); the average half-life value was 35 mm,
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FIg. 3. The plasma half-life of d-amphetamine and the rate of formation
of p-hydroxyamphetamine. d-Amphetamine was administered at a dose
of 1 0 mg/kg and plasma half-life of the drug was determined (#{149}).An
average half-life of 36 mm was obtained. The rate of formation and
elimination of p-hydroxyamphetamine was also determined (0). The
kinetic constants for formation and elimination of p-hydroxyampheta-
mine are given in the text.
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Fig. 4. Infusion of d-amphetamine and evoked changes in heart rate.
d-Amphetamine was continuously infused for 1 80 mm and evoked
changes in heart rate were monitored. Data are presented as percent
maximum response; actual data are presented in the text. Heart rate
responses attained steady state within 1 00 to 1 20 mm. Continued
infusion of drug led to no further increases in heart rate.
Plasma levels of p-hydroxyamphetamine were determined
after the administration of d-amphetamine (10 mg/kg, fig. 3).
The data indicate that plasma levels of d-amphetamine consid-
erably exceeded those of p-hydroxyamphetamine.
In addition to the empirical data, two kinetic indices were
determined: the rate constant for biotransformation of d-am-
phetamine top-hydroxyamphetamine and the rate constant for
elimination of p-hydroxyamphetamine. The rate constant for
biotransformation was estimated as follows. The rate constant
for elimination of d-amphetamine is 0.0197 - min’ (see
above). The fractional conversion of d-amphetamine to p-hy-
droxyamphetarnine is 0.5 (Dring et al., 1970; L. Simpson,
unpublished observations). Therefore, the rate constant for
biotransformation is 0.0099 - min’. The rate constant for
elimination of p-hydroxyamphetamine has been determined
from plasma half-life studies and is  0.049 . rnjn’ (Simpson,
1979).
Infusion of d-amphetamine and evoked changes in
heart rate. d-Amphetamine was infused at a constant rate of
0.54 tg/min which evoked a maximal heart rate response of 101
± 13 beats/mm (n = 5). The maximal response was ordinarily
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Fig. 5. Infusion of d-amphetamine and evoked changes in blood pres-
sure. The figure illustrates an experiment in which d-amphetamine was
continuously infused for 1 20 mm, and evoked changes in blood pres-
sure were monitored. The data represent the average responses ob-
tamed from 1 0 animals. For each data point, the S.D. is egual to or
less than 7% of the average response. Data are presented as percent
maximum response. Note that a peak response was attained within 10
mm, after which the response decayed. Response decay occurred
even though d-amphetamine was still being infused.
attained within 100 to 120 min (fig. 4). When steady state had
been attained, continued infusion of the drug led to no further
increases or decreases in heart rate. The amount of time nec-
essary to achieve a plateau in response magnitude (100 to 120
mm) was approximately equivalent to the amount of time
necessary to achieve a plateau (-.-90%) in plasma concentration
of drug (-‘-116 miii; 3.3 x T112 elimination).
Infusion of d-amphetamine and evoked changes in
blood pressure. d-Amphetamine was infused at several rates
(8-80 g/min) that evoked peak blood pressure responses in the
range of 40 to 70 mm Hg. A representative experiment is
ifiustrated in figure 5 (infusion rate = 80 g/min). For each of
the infusion rates tested, the evoked changes in blood pressure
possessed two characteristic features: 1) the amount of time
necessary to achieve a peak in response magnitude (e.g., fig. 5)
was less than the amount of time necessary to achieve a plateau
in plasma concentration of drug (-116 mm, see above) and 2)
the peak response was not well maintained but instead decayed
with time.
A similar series of experiments was done on animals that had
been pretreated with iprindole (10 mg/kg i.p., 30 mm), an agent
that inhibits hydroxylation of d-amphetamine (Freeman and
Sulser, 1972). Pretreatment with iprindole did not alter the
pattern of d-amphetamine-induced pressor responses. As in the
control situation, responses quickly attained a peak and then
decayed with time.
Discussion
Responses to singleinjections of d-amphetamine. The
administration of d-amphetamine can evoke a variety of re-
sponses; the administration of the hydroxylated metabolites of
d-amphetamine can evoke many of the same responses (Le-
wander, 1977). These facts prompt a logical question: are re-
sponses to the administration of d-amphetamine mediated in
part by the metabolites? More precisely, are the metabolites
involved in the immediate response, tachyphylactic response or
tolerant response to d-amphetamine? The present study ad-
dresses the first and second of the possibilities. The role of
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To determine whether a drug metabolite is involved in re-
sponses evoked by a parent compound, one must obtain at least
four types of information (see “Introduction”). The present
study, when combined with previously published reports, pro-
vides that information. The data can be used to show that the
hydroxy!ated metabolites play little role in acute responses to
d-amphetamine. The reasoning to support this claim is as
follows.
p-Hydroxyamphetamine can be viewed as a substitute am-
phetamine. The metabolite (Simpson, 1979), like the parent
compound (Weiss and Costa, 1968; Bylund and Snyder, 1976;
Smith et al., 1977), possesses little agonistic activity. In addition,
the metabolite lacks antagonistic activity at the receptor (fig.
1) and it lacks both antagonistic and synergistic activity pre-
synaptically (fig. 2). The fact that chemical sympathectomy
attenuates responses to p-hydroxyamphetamine (Simpson,
1979) indicates that this compound, like d-amphetamine, is an
indirectly acting sympathomimetic amine.
Although the parent compound and the metabolite have
similar mechanisms of action, they have slightly different po-
tencies. In relation to evoked changes in heart rate, p-hydroxy-
amphetamine is approximately twice as potent as d-amphet-
amine (fig. 2; and compare fig. 4 in Simpson, 1978b with figure
5 in Simpson, 1979). The metabolite is also more potent in
blocking the high affinity norepinephrine uptake system and in
evoking norepinephrine release from chopped cerebral cortex
(Wenger and Rutledge, 1974). Thus, p-hydroxyamphetamine is
a substitute d-arnphetamine, but a substitute ofslightly greater
potency.
The extent to whichp-hydroxyamphetamine can accumulate
in vivo hinges upon two interrelated determinants, the frac-
tional conversion ofd-amphetamine top-hydroxyamphetamine
and the rate constants for formation and elimination of p-
hydroxyamphetamine. The rate constant for absorption of d-
amphetamine is not relevant because the drug was administered
as an intravenous bolus.
The fractional conversion of d-amphetamine to p-hydroxy-
amphetamine varies considerably among species (Dring et al.,
1970). Values encompass at least one order ofmagnitude (-0.05
or less, guinea pig and man; -0.5, rat). In addition, there are
numerous factors that can influence route and rate of d-am-
phetamine elimination within species. Nevertheless, an esti-
mate of 0.5 for fractional conversion in the rat appears to be
reasonable.
The fact that a substantial amount of d-amphetamine is
converted to p-hydroxyamphetamine, and that the metabolite
is slightly more potent than the parent compound, might seem
to implicate the metabolite in responses to d-amphet.amine.
However, the factors tending to implicate p-hydroxyampheta-
mine are offset by certain kinetic measures. The rate of for-
mation of p-hydroxyamphetamine (0.0099 . min’) is slow
compared to the rate of elimination of the drug (0.049 . min).
As a result, plasma levels of the parent compound substantially
exceed those of the metabolite for an interval of time encom-
passing many half-lives for both drugs (e.g., fig. 3). Any putative
contribution made by the metabolite is largely obscured by the
excess parent compound.
The matters just discussed make it unlikely that p-hydroxy-
amphetamine contributes importantly to the immediate re-
sponse evoked by a single injection of d-amphetamine. By
extension, one can conclude that the second metabolite, p-
hydroxynorephedrine, contributes nothing.
Responses to multiple injections of d-amphetamine.
The purpose ofthis section is to consider a special circumStance,
that being the case in which multiple injections of d-amphet-
amine lead to the development of tachyphylaxis. Multiple in-
jections of a drug, if given at appropriately short intervals, will
cause accumulation of both the parent compound and its me-
tabolites. Conceivably, accumulation of a metabolite could con-
tribute to the development of tachyphylaxis.
In a previous study (Simpson, 1978b), the phenomenon of
tachyphylaxis was examined in some detail. This study placed
considerable emphasis on measuring responses and plasma
levels of drug under conditions that approximate steady state.
The concept of measuring responses at steady state has been
employed in the present study as well. Steady state, or ap-
proaches to steady state, have been achieved by constant intra-
venous infusion of drug.
Data from the infusion experiments support three conclu-
sions: 1) d-amphetamine does not elicit tachyphylaxis in rela-
tion to heart rate responses; 2) d-amphetamine does elicit
tachyphylaxis in relation to blood pressure responses; and 3)
neither p-hydroxyamphetamine nor p-hydroxynorephedrine is
involved in tachyphylaxis to d-amphetamine-induced pressor
responses.
Figure 4 shows an absence of tachyphylaxis to d-amphet-
amine-induced changes in heart rate. Constant intravenous
infusion of the drug produced an increase in heart rate and an
approach to steady state that were in keeping with the phar-
macokinetics of d-amphetamine. Continuous infusion beyond
the amount of time necessary to produce steady-state plasma
levels of drug did not produce a decay in response magnitude.
An absence of response decay in the continued presence of drug
argues against the existence of tachyphylaxis. This obviates the
question of whether the hydroxylated metabolites are involved
in tachyphylaxis.
Figure 5 shows that d-amphetamine does cause tachyphylaxis
in relation to blood pressure responses. Response magnitude
attains a peak long before plasma levels of drug attain steady
state. Furthermore, responses decay in the continued presence
of d-amphetamine. Response decay in the continued presence
of drug argues for the existence of tachyphylaxis.
It is unlikely that the hydroxylated metabolites contribute
importantly to tachyphylaxis in blood pressure responses.
Tachyphylaxis emerges so quickly that the metabolites do not
have sufficient time to accumulate. This reasoning is compatible
with the observation that inhibition of d-amphetamine bio-
transformation to p-hydroxyamphetamine does not impair the
ability of the parent compound to evoke tachyphylaxis. By
extension, one can rule out any putative role for p-hydroxyno-
rephedrine.
The data and conclusions that pertain to repeated injections
of d-amphetamine must be viewed within two limitations.
Firstly, responses have been studied only in the rat. The extent
to which heart rate refractoriness to tachyphylaxis and blood
pressure susceptibility to tachyphylaxis occur in other animals
is undetermined. Secondly, this study considers the responses
to d-amphetamine administered repeatedly on an acute time
scale. It is unknown whether the hydroxylated metabolites are
involved in responses to d-amphetamine administered repeat-
edly on a chronic time scale.
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